Drug Profile
Research programme: metabolic disorders therapy - BioFocus/Teijin
Latest Information Update: 15 Apr 2014
Price :
$50
*
At a glance
- Originator BioFocus DPI; Teijin Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Metabolic disorders
Most Recent Events
- 31 Mar 2014 BioFocus has been acquired by Charles River Laboratories
- 04 Feb 2003 No development reported - Preclinical for Metabolic disorders in United Kingdom (unspecified route)
- 04 Jul 2001 Cambridge Drug Discovery has been acquired by BioFocus